New Pill & Immunotherapy Boost Ovarian Cancer Survival

Relacorilant, a pill used for Cushings syndrome, combined with nab-paclitaxel, showed promising results in a trial with 381 patients with platinum-resistant ovarian cancer. The combination reduced the risk of death by 35% and increased median survival to 16 months. Another Lancet study found that pembrolizumab, an immunotherapy drug, also improved survival. These findings offer hope and could reshape treatment options for this aggressive cancer. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/4898775605c3bca1